Skip to main content

Advertisement

SpringerLink
Log in

Is it time to say goodbye to weekly rituximab in ANCA vasculitis?

  • Letter to the Editor
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mittal S, Naidu GSRSNK, Jha S, Rathi M, Nada R, Minz RW, Sharma K, Dhir V, Jain S, Sharma A (2020) Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis—a real-life experience. Clin Rheumatol. https://doi.org/10.1007/s10067-020-05261-7

  2. Shobha V, Rao V, Desai A, Jois R, Srikantiah C, Dharmanand B, Kumar S, Kumar P, Dharmapalaiah C, Mahendranath KM, Prasad S, Daware M, Singh Y, Karjigi U (2019) Prescribing patterns and safety of biologics in immune-mediated rheumatic diseases: Karnataka biologics cohort study group experience. Indian J Rheumatol 14(1):17

    Article  Google Scholar 

  3. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363(3):221–232

    Article  CAS  Google Scholar 

  4. Jones RB, Cohen Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363(3):211–220

    Article  CAS  Google Scholar 

  5. Golay J, Semenzato G, Rambaldi A, Foà R, Gaidano G, Gamba E, Pane F, Pinto A, Specchia G, Zaja F, Regazzi M (2013) Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs. 5(6):826–837

    Article  Google Scholar 

  6. Cornec D, Kabat BF, Mills JR, Cheu M, Hummel AM, Schroeder DR et al (2018) Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. Rheumatol (United Kingdom) 57(4):639–650

    CAS  Google Scholar 

  7. Gayatri E, Dhaval T, Natasha N, Muzaffar B, Dhiren R, Lucky S et al (2019) Rituximab in relapsed/refractory antineutrophil cytoplasmic antibody associated vasculitis: a single-center prospective observational study. Indian J Rheumatol 14(1):12–16

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Immunology and Rheumatology, St John’s Medical College, Sarjapur Road, Bengaluru, 560034, India

    Benzeeta Pinto

  2. Department of Clinical Immunology and Rheumatology, Santokba Durlabhji Memorial Hospital, Jaipur, India

    Aadhaar Dhooria

Authors
  1. Benzeeta Pinto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aadhaar Dhooria
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benzeeta Pinto.

Ethics declarations

Disclosures

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pinto, B., Dhooria, A. Is it time to say goodbye to weekly rituximab in ANCA vasculitis?. Clin Rheumatol 39, 3153–3154 (2020). https://doi.org/10.1007/s10067-020-05360-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-020-05360-5

Search

Navigation